Evotec AG today announced that it has been awarded a research grant from The Michael J. Fox Foundation („MJFF“) to further develop Evotec’s TargetaSN (Targetalpha-synuclein) programme for the treatment of Parkinson’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-awarded-grant-from-the-michael-j-fox-foundation-for-parkinsons-research-5339